Your Source for Venture Capital and Private Equity Financings

Evommune Snags $12M in Seed Funding

2020-11-18
LOS ALTOS, CA, Evommune announced the successful completion of a $12.5 million seed financing.
Evommune, Inc., an innovation engine in chronic inflammation, announced the successful completion of a $12.5 million seed financing by Pivotal bioVenture Partners. This financing will enable Evommune to build a pipeline of unique therapies for patients with chronic inflammatory diseases.

Evommune is a private, R&D company and innovation engine in chronic inflammation. Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases. Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases. The company is headquartered in Los Altos, California.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors